OnKure Therapeutics, Inc. (OKUR) stock
Close on Oct 30, 2026Market cap $106.10MP/E –Yield –
Earnings
OnKure Therapeutics's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.
Quarterly results
Revenue and earnings per share from each of OnKure Therapeutics's earnings releases, newest first
| Quarter | Reported | Revenue | YoY | EPS | Source |
|---|---|---|---|---|---|
| Q3 FY2026ended Sep 30, 2026 | Nov 5, 2026Expected | – | – | – | – |
| Q2 FY2026ended Jun 30, 2026 | Aug 4, 2026after the close | – | – | -$0.31 | Release |
| Q1 FY2026ended Mar 31, 2026 | May 5, 2026after the close | – | – | – | Release |
| Q4 FY2025ended Dec 31, 2025 | Mar 12, 2026after the close | – | – | -$0.99 | Release |
| Q3 FY2025ended Sep 30, 2025 | Nov 6, 2025after the close | – | – | -$1.09 | Release |
| Q2 FY2025ended Jun 30, 2025 | Aug 12, 2025after the close | – | – | -$1.14 | Release |
| Q1 FY2025ended Mar 31, 2025 | May 6, 2025before the open | – | – | -$1.19 | Release |
| Q4 FY2024ended Dec 31, 2024 | Mar 10, 2025after the close | – | – | -$1.37 | Release |
| Q2 FY2024ended Jun 30, 2024 | Aug 13, 2024after the close | – | – | – | Release |
| Q1 FY2024ended Mar 31, 2024 | May 7, 2024after the close | – | – | -$0.25 | Release |
| Q4 FY2023ended Dec 31, 2023 | Mar 28, 2024after the close | – | – | -$0.70 | Release |
| Q3 FY2023ended Sep 30, 2023 | Nov 13, 2023after the close | – | – | -$0.57 | Release |
| Q2 FY2023ended Jun 30, 2023 | Aug 10, 2023after the close | – | – | -$0.65 | Release |
| Q1 FY2023ended Mar 31, 2023 | May 11, 2023after the close | – | – | -$0.60 | Release |
| Q4 FY2022ended Dec 31, 2022 | Mar 27, 2023after the close | – | – | -$0.56 | Release |
| Q3 FY2022ended Sep 30, 2022 | Nov 8, 2022after the close | – | – | -$0.53 | Release |
| Q2 FY2022ended Jun 30, 2022 | Aug 9, 2022after the close | – | – | -$0.50 | Release |
| Q1 FY2022ended Mar 31, 2022 | May 10, 2022after the close | – | – | -$0.53 | Release |
| Q4 FY2021ended Dec 31, 2021 | Mar 23, 2022after the close | – | – | -$0.43 | Release |
| Q3 FY2021ended Sep 30, 2021 | Nov 12, 2021before the open | – | – | -$0.52 | Release |
| Q2 FY2021ended Jun 30, 2021 | Aug 11, 2021before the open | – | – | – | Filing |
| Q1 FY2021ended Mar 31, 2021 | May 20, 2021before the open | – | – | – | Filing |
Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.
Current guidance
No open guidance: every period OnKure Therapeutics guided for has been reported
Guidance history
Every forecast OnKure Therapeutics put in an earnings release, newest first
| Given | Metric | Period | Guidance | Change |
|---|---|---|---|---|
| Mar 28, 2024 | cash, cash equivalents, and short-term investments | Q1 FY2024 | $82.00M | New |
Read from the company's earnings releases; each figure links to its sentence on hover. “Raised” and “Lowered” compare with the previous range for the same metric and period.
Press releases
Releases OnKure Therapeutics filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Results
- Results
- Results
- Results
- Update
- Results
- Results
- Update
- Update
- News
- News
- News
- Update
- Update